Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Boucher, CAB' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 73 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Stuart, JWTC; Wensing, AMJ; Kovacs, C; Righart, M; de Jong, D; Kaye, S; Schuurman, R; Visser, CJT; Boucher, CAB
      Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    2. van Elden, LJR; van Essen, GA; Boucher, CAB; van Loon, AM; Nijhuis, M; Schipper, P; Verheij, TJM; Hoepelman, IM
      Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice

      BRITISH JOURNAL OF GENERAL PRACTICE
    3. Wensing, AMJ; Reedijk, M; Richter, C; Boucher, CAB; Borleffs, JCC
      Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels

      AIDS
    4. Mascolini, M; Wensing, AMJ; Boucher, CAB
      HIV resistance assay results and their effect on therapeutic decisions

      AIDS
    5. van Esser, JWJ; Niesters, HGM; Thijsen, SFT; Meijer, E; Osterhaus, ADME; Wolthers, KC; Boucher, CAB; Gratama, JW; Budel, LM; van der Holt, B; van Loon, AM; Lowenberg, B; Verdonck, LF; Cornelissen, JJ
      Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation

      BRITISH JOURNAL OF HAEMATOLOGY
    6. Stuart, JWTC; Hazebergh, MD; Hamann, D; Otto, SA; Borleffs, JCC; Miedema, F; Boucher, CAB; de Boer, RJ
      The dominant source of CD4(+) and CD8(+) T-cell activation in HIV infection is antigenic stimulation

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    7. Clevenbergh, P; Durant, J; Halfon, P; del Giudice, P; Mondain, V; Montagne, N; Schapiro, JM; Boucher, CAB; Dellamonica, P
      Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up

      ANTIVIRAL THERAPY
    8. Hazenberg, MD; Otto, SA; Stuart, JWTC; Verschuren, MCM; Borleffs, JCC; Boucher, CAB; Coutinho, RA; Lange, JMA; De Wit, TFR; Tsegaye, A; Van Dongen, JJM; Hamann, D; De Boer, RJ; Miedema, F
      Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection

      NATURE MEDICINE
    9. Back, NKT; van Wijk, A; Remmerswaal, D; van Monfort, M; Nijhuis, M; Schuurman, R; Boucher, CAB
      In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

      AIDS
    10. Van Vaerenbergh, K; Van Laethem, K; Albert, J; Boucher, CAB; Clotet, B; Floridia, M; Gerstoft, J; Hejdeman, B; Nielsen, C; Pannecouque, C; Perrin, L; Pirillo, MF; Ruiz, L; Schmit, JC; Schneider, F; Schoolmeester, A; Schuurman, R; Stellbrink, HJ; Stuyver, L; Van Lunzen, J; Van Remoortel, B; Van Wijngaerden, E; Vella, S; Witvrouw, M; Yerly, S; De Clercq, E; Desmyter, J; Vandamme, AM
      Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    11. Maree, AFM; Keulen, W; Boucher, CAB; De Boer, RJ
      Estimating relative fitness in viral competition experiments

      JOURNAL OF VIROLOGY
    12. Frost, SDW; Nijhuis, M; Schuurman, R; Boucher, CAB; Brown, AJL
      Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

      JOURNAL OF VIROLOGY
    13. Sevin, AD; DeGruttola, V; Nijhuis, M; Schapiro, JM; Foulkes, AS; Para, MF; Boucher, CAB
      Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333

      JOURNAL OF INFECTIOUS DISEASES
    14. Orendi, JM; Nottet, HSLM; de Vos, NM; Visser, MR; Snippe, H; Boucher, CAB; Verhoef, J
      Hydroxyurea interferes with antigen-dependent T-cell activation in vitro

      EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
    15. Hazenberg, MD; Stuart, JWTC; Otto, SA; Borleffs, JCC; Boucher, CAB; de Boer, RJ; Miedema, F; Hamann, D
      T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)

      BLOOD
    16. Kamp, W; Schokker, J; Cambridge, E; De Jong, S; Schuurman, R; De Groot, T; Boucher, CAB
      Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results ofa Phase I/II study

      ANTIVIRAL THERAPY
    17. Boucher, CAB
      HIV drug resistance tests are here to stay

      CURRENT OPINION IN INFECTIOUS DISEASES
    18. Been-Tiktak, AMM; Boucher, CAB; Brun-Vezinet, F; Joly, V; Mulder, JW; Jost, J; Cooper, DA; Moroni, M; Gatell, JM; Staszewski, S; Colebunders, R; Stewart, GJ; Hawkins, DA; Johnson, MA; Parkin, JM; Kennedy, DH; Hoy, JF; Borleffs, JCC
      Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial

      INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
    19. Stuart, JWTC; Schuurman, R; Burger, DM; Koopmans, PP; Sprengers, HG; Juttmann, JR; Richter, C; Meenhorst, PL; Hoetelmans, RMW; Kroon, FP; Bravenboer, B; Hamann, D; Boucher, CAB; Borleffs, JCC
      Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)

      AIDS
    20. Nijhuis, M; Schuurman, R; de Jong, D; Erickson, J; Gustchina, E; Albert, J; Schipper, P; Gulnik, S; Boucher, CAB
      Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

      AIDS
    21. Keulen, W; van Wijk, A; Schuurman, R; Berkhout, B; Boucher, CAB
      Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential

      AIDS
    22. Durant, J; Clevenbergh, P; Halfon, P; Delgiudice, P; Porsin, S; Simonet, P; Montagne, N; Boucher, CAB; Schapiro, JM; Dellamonica, P
      Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial

      LANCET
    23. BRUISTEN SM; REISS P; LOELIGER AE; VANSWIETEN P; SCHUURMAN R; BOUCHER CAB; WEVERLING GJ; HUISMAN JG
      CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS

      AIDS research and human retroviruses
    24. STUART JWTC; SLIEKER WAT; RIJKERS GT; NOEST A; BOUCHER CAB; SUUR MH; DEBOER R; GEELEN SPM; SCHERPBIER HJ; HARTWIG NG; HOOIJKAAS H; ROOS MT; DEGRAEFFMEEDER B; DEGROOT R
      EARLY RECOVERY OF CD4-LYMPHOCYTES IN CHILDREN ON HIGHLY-ACTIVE ANTIRETROVIRAL THERAPY( T)

      AIDS
    25. DEBOER RJ; BOUCHER CAB; PERELSON AS
      TARGET-CELL AVAILABILITY AND THE SUCCESSFUL SUPPRESSION OF HIV BY HYDROXYUREA AND DIDANOSINE

      AIDS
    26. WOUT ABVT; RAN LJ; NIJHUIS M; TIJNAGEL JMGH; DEGROOT T; VANLEEUWEN R; BOUCHER CAB; SCHUITEMAKER H; SCHUURMAN R
      EFFICIENT INHIBITION OF BOTH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING WILD-TYPE HIV-1 BY LAMIVUDINE IN-VIVO

      AIDS
    27. DEJONG MD; BOUCHER CAB; DANNER SA; GAZZARD B; GRIFFITHS PD; KATLAMA C; LANGE JMA; RICHMAN DD; VELLA S
      SUMMARY OF THE INTERNATIONAL CONSENSUS SYMPOSIUM ON MANAGEMENT OF HIV, CMV AND HEPATITIS-VIRUS INFECTIONS

      Antiviral research
    28. BRINKMAN K; HUYSMANS F; GALAMA JMD; BOUCHER CAB
      IN-VIVO ANTI-CD3-INDUCED HIV-1 VIREMIA

      Lancet
    29. NIJHUIS M; BOUCHER CAB; SCHIPPER P; LEITNER T; SCHUURMAN R; ALBERT J
      STOCHASTIC-PROCESSES STRONGLY INFLUENCE HIV-1 EVOLUTION DURING SUBOPTIMAL PROTEASE-INHIBITOR THERAPY

      Proceedings of the National Academy of Sciences of the United Statesof America
    30. ORENDI JM; BLOEM AC; BORLEFFS JCC; WIJNHOLDS FJ; DEVOS NM; NOTTET HSLM; VISSER MR; SNIPPE H; VERHOEF J; BOUCHER CAB
      ACTIVATION AND CELL-CYCLE ANTIGENS IN CD4(-CELLS CORRELATE WITH PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS (HIV-1) RNA LEVEL IN HIV-1 INFECTION() AND CD8(+) T)

      The Journal of infectious diseases
    31. COLL O; HERNANDEZ M; BOUCHER CAB; FORTUNY C; DETEJADA BM; CANET Y; CARAGOL I; TIJNAGEL J; BERTRAN JM; ESPANOL T
      VERTICAL HIV-1 TRANSMISSION CORRELATES WITH A HIGH MATERNAL VIRAL LOAD AT DELIVERY

      Journal of acquired immune deficiency syndromes and human retrovirology
    32. NIJHUIS M; SCHUURMAN R; BOUCHER CAB
      HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV

      Current opinion in infectious diseases
    33. BEENTIKTAK AMM; DEHAAS CJC; DEGRAAF L; BOUCHER CAB; VERHOEF J; BORLEFFS JCC; NOTTET HSLM; SCHUURMAN R
      IN-VITRO SELECTION OF HIV-1 VARIANTS RESISTANT TO NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS IN MONOCYTE-DERIVED MACROPHAGES

      Journal of antimicrobial chemotherapy
    34. DEJONG MD; DEBOER RJ; DEWOLF F; FOUDRAINE NA; BOUCHER CAB; GOUDSMIT J; LANGE JMA
      OVERSHOOT OF HIV-1 VIREMIA AFTER EARLY DISCONTINUATION OF ANTIRETROVIRAL TREATMENT

      AIDS
    35. MILLER V; STASZEWSKI S; BOUCHER CAB; PHAIR JP
      CLINICAL-EXPERIENCE WITH NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS

      AIDS
    36. DEJONG MD; BOUCHER CAB; COOPER DA; GALASSO GJ; GAZZARD B; LANGE JMA; MONTANER JS; RICHMAN DD; THOMAS HC
      SUMMARY OF THE 2ND INTERNATIONAL CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY AND IMPLICATIONS FOR FUTURE THERAPIES

      Antiviral research
    37. KEULEN W; BACK NKT; VANWIJK A; BOUCHER CAB; BERKHOUT B
      INITIAL APPEARANCE OF THE 184ILE VARIANT IN LAMIVUDINE-TREATED PATIENTS IS CAUSED BY THE MUTATIONAL BIAS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE

      Journal of virology
    38. STILIANAKIS NI; BOUCHER CAB; DEJONG MD; VANLEEUWEN R; SCHUURMAN R; DEBOER RJ
      CLINICAL-DATA SETS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE TRANSCRIPTASE-RESISTANT MUTANTS EXPLAINED BY A MATHEMATICAL-MODEL

      Journal of virology
    39. NIJHUIS M; SCHUURMAN R; DEJONG D; VANLEEUWEN R; LANGE J; DANNER S; KEULEN W; DEGROOT T; BOUCHER CAB
      LAMIVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS (184V) REQUIRE MULTIPLE AMINO-ACID CHANGES TO BECOME CO-RESISTANT TO ZIDOVUDINE IN-VIVO

      The Journal of infectious diseases
    40. DEJONG MD; VELLA S; CARR A; BOUCHER CAB; IMRIE A; FRENCH M; HOY J; SORICE S; PAULUZZI S; CHIODO F; WEVERLING GJ; VANDERENDE ME; FRISSEN PJ; WEIGEL HM; KAUFFMANN RH; LANGE JMA; YOON R; MORONI M; HOENDERDOS E; LEITZ G; COOPER DA; HALL D; REISS P
      HIGH-DOSE NEVIRAPINE IN PREVIOUSLY UNTREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT RESULT IN SUSTAINED SUPPRESSION OF VIRAL REPLICATION

      The Journal of infectious diseases
    41. VANTWOUT AB; RAN LJ; DEJONG MD; BAKKER M; VANLEEUWEN R; NOTERMANS DW; LOELIGER AE; DEWOLF F; DANNER SA; REISS P; BOUCHER CAB; LANGE JMA; SCHUITEMAKER H
      SELECTIVE-INHIBITION OF SYNCYTIUM-INDUCING AND NONSYNCYTIUM-INDUCING HIV-1 VARIANTS IN INDIVIDUALS RECEIVING DIDANOSINE OR ZIDOVUDINE, RESPECTIVELY

      The Journal of clinical investigation
    42. MOLLA A; KORNEYEVA M; GAO Q; VASAVANONDA S; SCHIPPER PJ; MO HM; MARKOWITZ M; CHERNYAVSKIY T; NIU P; LYONS N; HSU A; GRANNEMAN GR; HO DD; BOUCHER CAB; LEONARD JM; NORBECK DW; KEMPF DJ
      ORDERED ACCUMULATION OF MUTATIONS IN HIV PROTEASE CONFERS RESISTANCE TO RITONAVIR

      Nature medicine
    43. DEBOER RJ; BOUCHER CAB
      ANTI-CD4 THERAPY FOR AIDS SUGGESTED BY MATHEMATICAL-MODELS

      Proceedings - Royal Society. Biological Sciences
    44. BOUCHER CAB
      INDIVIDUALIZATION OF HIV THERAPY BASED ON HIV RNA LOAD - THE VIROLOGISTS PERSPECTIVE

      International journal of antimicrobial agents
    45. BACK NKT; NIJHUIS M; KEULEN W; BOUCHER CAB; ESSINK BBO; VANKUILENBURG ABP; VANGENNIP AH; BERKHOUT B
      REDUCED REPLICATION OF 3TC-RESISTANT HIV-1 VARIANTS IN PRIMARY-CELLS DUE TO A PROCESSIVITY DEFECT OF THE REVERSE-TRANSCRIPTASE ENZYME

      EMBO journal
    46. DEJONG MD; BOUCHER CAB; GALASSO GJ; HIRSCH MS; KERN ER; LANGE JMA; RICHMAN DD
      CONSENSUS SYMPOSIUM ON COMBINED ANTIVIRAL THERAPY

      Antiviral research
    47. SCHUURMAN R; DESCAMPS D; WEVERLING GJ; KAYE S; TIJNAGEL J; WILLIAMS I; VANLEEUWEN R; TEDDER R; BOUCHER CAB; BRUNVEZINET F; LOVEDAY C
      MULTICENTER COMPARISON OF 3 COMMERCIAL METHODS FOR QUANTIFICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA IN PLASMA

      Journal of clinical microbiology
    48. BEENTIKTAK AMM; WILLIAMS I; VREHEN HM; RICHENS J; ALDAM D; VANLOON AM; LOVEDAY C; BOUCHER CAB; WARD P; WELLER IVD; BORLEFFS JCC
      SAFETY, TOLERANCE, AND EFFICACY OF ATEVIRDINE IN ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS

      Antimicrobial agents and chemotherapy
    49. BOUCHER CAB; KEULEN W; VANBOMMEL T; NIJHUIS M; DEJONG D; DEJONG MD; SCHIPPER P; BACK NKT
      HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DRUG SUSCEPTIBILITY DETERMINATIONBY USING RECOMBINANT VIRUSES GENERATED FROM PATIENT SERA TESTED IN A CELL-KILLING ASSAY

      Antimicrobial agents and chemotherapy
    50. DEJONG MD; VEENSTRA J; STILIANAKIS NI; SCHUURMAN R; LANGE JMA; DEBOER RJ; BOUCHER CAB
      HOST-PARASITE DYNAMICS AND OUTGROWTH OF VIRUS CONTAINING A SINGLE K70R AMINO-ACID CHANGE IN REVERSE-TRANSCRIPTASE ARE RESPONSIBLE FOR THE LOSS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA LOAD SUPPRESSION BY ZIDOVUDINE

      Proceedings of the National Academy of Sciences of the United Statesof America
    51. VANTWOUT AB; DEJONG MD; KOOTSTRA NA; VEENSTRA J; LANGE JMA; BOUCHER CAB; SCHUITEMAKER H
      CHANGES IN CELLULAR VIRUS LOAD AND ZIDOVUDINE RESISTANCE OF SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING HUMAN-IMMUNODEFICIENCY-VIRUS POPULATIONS UNDER ZIDOVUDINE PRESSURE - A CLONAL ANALYSIS

      The Journal of infectious diseases
    52. DEJONG MD; VEENSTRA J; STILIANAKIS N; SCHUURMAN R; DEBOER RJ; LANGE JMA; BOUCHER CAB
      RETURN TO BASE-LINE VALUES OF HIV-1 RNA LOAD DURING ZIDOVUDINE TREATMENT IS ASSOCIATED WITH THE EMERGENCE OF K70R MUTANT VIRUS

      Journal of acquired immune deficiency syndromes and human retrovirology
    53. VANTWOUT AB; DEJONG MD; KOOTSTRA NA; SCHUURMAN R; COUTINHO R; BOUCHER CAB; SCHUITEMAKER H
      PREFERENTIAL INHIBITION OF NON-SYNCYTIUM-INDUCING HIV-1 VARIANTS BY ZIDOVUDINE

      Journal of acquired immune deficiency syndromes and human retrovirology
    54. DANNER SA; CARR A; LEONARD JM; LEHMAN LM; GUDIOL F; GONZALES J; RAVENTOS A; RUBIO R; BOUZA E; PINTADO V; AGUADO AG; DELGADO R; BORLEFFS JCC; HSU A; VALDES JM; BOUCHER CAB; COOPER DA
      SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE

      Journal of acquired immune deficiency syndromes and human retrovirology
    55. DEJONG MD; SCHUURMAN R; LANGE JMA; BOUCHER CAB
      RAPID SELECTIVE OUTGROWTH OF A MINOR PREEXISTING DRUG-RESISTANT HIV-1SUBPOPULATION DURING SUBSEQUENT NEVIRAPINE TREATMENT

      Journal of acquired immune deficiency syndromes and human retrovirology
    56. VEENSTRA J; SCHUURMAN R; CORNELISSEN M; VANTWOUT AB; BOUCHER CAB; SCHUITEMAKER H; GOUDSMIT J; COUTINHO RA
      TRANSMISSION OF ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS FOLLOWING DELIBERATE INJECTION OF BLOOD FROM A PATIENT WITH AIDS - CHARACTERISTICS AND NATURAL-HISTORY OF THE VIRUS

      Clinical infectious diseases
    57. NIJHUIS M; BOUCHER CAB; SCHUURMAN R
      SENSITIVE PROCEDURE FOR THE AMPLIFICATION OF HIV-1 RNA USING A COMBINED REVERSE-TRANSCRIPTION AND AMPLIFICATION REACTION

      BioTechniques
    58. BOUCHER CAB; REEDIJK M
      VIRAL RESISTANCE - A MAJOR CHALLENGE IN MANAGING HIV DISEASE

      Journal of biological regulators and homeostatic agents
    59. FERNANDEZCRUZ E; LANG JM; FRISSEN J; FURNER V; CHATEAUVERT M; BOUCHER CAB; DOWD P; STEVENS J; GOLD J; MICHELMORE H; BENSON E; SPELMAN E; HOY J; WRIGHT E; FRENCH M; HUDSON J; MALLAL S; BODSWORTH N; STINGL G; MAYERHOFER S; KRONAWETTER M; TSOUKAS C; SZABO T; KATLAMA C; GUERMONPREZ G; RAFFI F; BILLAUD E; MILPIED B; BOURGEOT V; FLEISHMANN M; BARRIER JH; DELZANT G; WINTER C; MEHARZI J; TREPO C; COTTE L; ROUGIER P; HASSAIRI N; CHOUTET P; BESNIER JM; LAFEUILLADE A; RASOKAT H; GROSS G; MAUSCH HE; STRATIGOS J; POLYDOROV D; STAVRIANEAS N; KIOSSES V; MANDALAKI T; KARAFOULIDOU A; KARABINIS A; STERGIOU G; PLOUMIDES G; PITSAS A; TASSOPOULOS N; KOUTSOUNOPOULOS G; HATZAKIS A; MORONI M; DARMINIO A; BINI T; CHIODO F; COLANGELI V; RICCHI E; AIUTI F; FERRARA R; MEZZAROMA I; LANGE JMA; FRISSEN PHJ; SPRENGER HG; KROON FP; VANDERENDE ME; DEMARIE S; KOOPMANS PP; DOLMANS WMV; SCHREIJ GS; WEIGEL HM; TENNAPEL CHH; TENKATE RW; MARANON G; ZABAY JM; COSIN J; PENA JM; RUBIO R; RIBERA E; VAZQUEZ JMM; LEAL M; ANDREU J; CARTON JA; ASENSI V; GOMEZTRUJILLO F; ORIHUELA F; SERRANO C; FERRER E; MANDAL BK; JOHNSON M; MCKARTHY K; FARMER D; TANG A; MITCHELL SA; BROWN J; TOORAWA R; YEO J
      ZIDOVUDINE PLUS INTERFERON-ALPHA VERSUS ZIDOVUDINE ALONE IN HIV-INFECTED SYMPTOMATIC OR ASYMPTOMATIC PERSONS WITH CD4-THAN-150X10(6)( CELL COUNTS GREATER)I - RESULTS OF THE ZIDON TRIAL/

      AIDS
    60. INGRAND D; WEBER J; BOUCHER CAB; LOVEDAY C; ROBERT C; HILL A; CAMMACK N; KATLAMA C; TUBIANA R; VALENTIN MA; GENTILINI M; VANLEEUWEN R; DANNER SA; KITCHEN V; MCBRIDE M
      PHASE-I PHASE-II STUDY OF 3TC (LAMIVUDINE) IN HIV-POSITIVE, ASYMPTOMATIC OR MILD AIDS-RELATED COMPLEX PATIENTS - SUSTAINED REDUCTION IN VIRAL MARKERS/

      AIDS
    61. REEDIJK M; BOUCHER CAB; VANBOMMEL T; HO DD; TZENG TB; SERENI D; VEYSSIER P; JURRIAANS S; GRANNEMAN R; HSU A; LEONARD JM; DANNER SA
      SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF A77003, A C-2 SYMMETRY-BASED HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR

      Antimicrobial agents and chemotherapy
    62. DANNER SA; CARR A; LEONARD JM; LEHMAN LM; GUDIOL F; GONZALES J; RAVENTOS A; RUBIO R; BOUZA E; PINTADO V; AGUADO AG; DELOMAS JG; DELGADO R; BORLEFFS JCC; HSU A; VALDES JM; BOUCHER CAB; COOPER DA; GIMENO C; CLOTET B; TOR J; FERRER E; MARTINEZ PL; MORENO S; ZANCADA G; ALCAMI J; NORIEGA AR; PULIDO F; GLASSMAN HN
      A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE

      The New England journal of medicine
    63. SCHUURMAN R; NIJHUIS M; VANLEEUWEN R; SCHIPPER P; DEJONG D; COLLIS P; DANNER SA; MULDER J; LOVEDAY C; CHRISTOPHERSON C; KWOK S; SNINSKY J; BOUCHER CAB
      RAPID CHANGES IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RNA LOAD AND APPEARANCE OF DRUG-RESISTANT VIRUS POPULATIONS IN PERSONS TREATED WITH LAMIVUDINE (3TC)

      The Journal of infectious diseases
    64. VANLEEUWEN R; KATLAMA C; KITCHEN V; BOUCHER CAB; TUBIANA R; MCBRIDE M; INGRAND D; WEBER J; HILL A; MCDADE H; DANNER SA
      EVALUATION OF SAFETY AND EFFICACY OF 3TC (LAMIVUDINE) IN PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE I II STUDY/

      The Journal of infectious diseases
    65. DEJONG MD; LOEWENTHAL M; BOUCHER CAB; VANDERENDE I; HALL D; SCHIPPER P; IMRIE A; WEIGEL HM; KAUFFMANN RH; KOSTER R; SEVILLE P; ROCKLIN R; COOPER DA; LANGE JMA
      ALTERNATING NEVIRAPINE AND ZIDOVUDINE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT PROLONG NEVIRAPINE ACTIVITY

      The Journal of infectious diseases
    66. FRISSEN PHJ; VANDERENDE ME; TENNAPEL CHH; WEIGEL HM; SCHREIJ GS; KAUFFMANN RH; KOOPMANS PP; HOEPELMAN AIM; DEBOER JB; WEVERLING GJ; HAVERKAMP G; DOWD P; MIEDEMA F; SCHUURMAN R; BOUCHER CAB; LANGE JMA
      ZIDOVUDINE AND INTERFERON-ALPHA, COMBINATION THERAPY VERSUS ZIDOVUDINE MONOTHERAPY IN SUBJECTS WITH SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

      The Journal of infectious diseases
    67. KELLAM P; BOUCHER CAB; TIJNAGEL JMGH; LARDER BA
      ZIDOVUDINE TREATMENT RESULTS IN THE SELECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS WHOSE GENOTYPES CONFER INCREASING LEVELS OF DRUG-RESISTANCE

      Journal of General Virology
    68. TERSMETTE M; KOOT M; BOUCHER CAB; MULDER JW; LANGE JMA; COUTINHO RA; MIEDEMA F
      PHENOTYPE-RELATED DIFFERENCES IN EFFICACY OF ZIDOVUDINE TREATMENT OF ASYMPTOMATIC HIV-1 INFECTED INDIVIDUALS

      Journal of cellular biochemistry
    69. LANGE JMA; TEEUWSEN VJP; BOUCHER CAB; VAHLNE A; BARIN F; TJONGAHUNG S; DEKKER J; PARKHEDE U; DEWOLF F; GOUDSMIT J
      ANTIGENIC VARIATION OF THE DOMINANT GP41-EPITOPE IN AFRICA

      AIDS
    70. ZWART G; WOLFS TFW; BOOKELMAN R; HARTMAN S; BAKKER M; BOUCHER CAB; KUIKEN C; GOUDSMIT J
      GREATER DIVERSITY OF THE HIV-1 V3 NEUTRALIZATION DOMAIN IN TANZANIA COMPARED WITH THE NETHERLANDS - SEROLOGICAL AND GENETIC-ANALYSIS

      AIDS
    71. BRUISTEN SM; KOPPELMAN MHGM; ROOS MTL; LOELIGER AE; REISS P; BOUCHER CAB; HUISMAN HG
      USE OF COMPETITIVE POLYMERASE CHAIN-REACTION TO DETERMINE HIV-1 LEVELS IN RESPONSE TO ANTIVIRAL TREATMENTS

      AIDS
    72. BOUCHER CAB; VANLEEUWEN R; KELLAM P; SCHIPPER P; TIJNAGEL J; LANGE JMA; LARDER BA
      EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES

      Antimicrobial agents and chemotherapy
    73. BOUCHER CAB; CAMMACK N; SCHIPPER P; SCHUURMAN R; ROUSE P; WAINBERG MA; CAMERON JM
      HIGH-LEVEL RESISTANCE TO (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE IN-VITRO IS DUE TO ONE AMINO-ACID SUBSTITUTION IN THE CATALYTIC SITE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE

      Antimicrobial agents and chemotherapy


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/05/20 alle ore 06:43:18